Jacob Abraham, MD
Advanced Heart Failure and Transplant Cardiology · Portland, ORNPI 1548223381
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (46.5%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 21 manufacturers reported payments, led by Abiomed at 58.9% of the total.
Across 617 payments — averaging $536.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$195K
- Abbott$97K
- Cvrx, Inc.$18K
- Endotronix, Inc.$10K
- Ancora Heart, Inc.$6K
- Impedimed, Inc.$1K
- plus $3K from 15 others
Across 86 payments — averaging $3800.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abbott$255K
- Impulse Dynamics (USA) Inc.$48K
- Medtronic$18K
- Novartis$6K
- Endotronix, Inc.$200
What the payments were for
- Consulting fees$115,88335%
- Speaking & faculty fees$153,95047%
- Travel & lodging$35,35011%
- Food & beverage$25,5758%
- Education$970%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 211 | $194,912 |
| Abbott | 264 | $96,872 |
| Cvrx, Inc. | 68 | $18,116 |
| Endotronix, Inc. | 4 | $10,257 |
| Ancora Heart, Inc. | 33 | $6,460 |
| Impedimed, Inc. | 1 | $1,000 |
| Biosense Webster, Inc. | 1 | $800 |
| Merit Medical Systems Inc | 1 | $600 |
| Medtronic(2 entities) | 11 | $395 |
| Edwards Lifesciences | 3 | $329 |
| Boehringer Ingelheim | 2 | $249 |
| AstraZeneca | 3 | $203 |
| Impulse Dynamics (USA) Inc. | 2 | $185 |
| ZOLL Respicardia, Inc. | 1 | $123 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $118 |
| American Regent | 1 | $87 |
| Cardiac Dimensions, Inc. | 2 | $61 |
| Nuwellis, Inc. | 1 | $33 |
| Penumbra, Inc. | 1 | $23 |
| Novartis | 1 | $20 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$165,516
- CARDIOMEMS$51,213
- CardioMEMS HF System$27,199
- Barostim Neo System$16,178
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$9,148
- AccuCinch$5,494
- FreeStyle Libre Pro$5,042
- HeartMate 3 Left Ventricular Dev$4,792
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$2,062
- HeartMate 3 Left Ventricular Assist Device$1,120
- CORDELLA PULMONARY ARTERY PRESSURE SENSOR$1,109
- Carto 3$800
- Mitra Clip system$500
- OPTIMIZER$276
- HeartMate$232
- JARDIANCE$125
- remede System$123
- HeartMate Touch$111
- HeartWare HVAD$110
- AMPLATZER TALISMAN$103
How this compares
Too few advanced heart failure and transplant cardiology providers in Oregonto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EntrestoSacubitril/Valsartan | 322 | $468,995 |
| FarxigaDapagliflozin Propanediol | 224 | $256,104 |
| EliquisApixaban | 168 | $216,213 |
| JardianceEmpagliflozin | 156 | $191,868 |
| XareltoRivaroxaban | 28 | $40,342 |
| Repatha SureclickEvolocumab | 27 | $19,569 |
| DapagliflozinDapagliflozin Propanediol | 21 | $12,500 |
| Metoprolol Succinate | 247 | $5,254 |
| Tacrolimus | 23 | $3,794 |
| Spironolactone | 317 | $3,709 |
| Bumetanide | 40 | $3,300 |
| Eplerenone | 48 | $3,107 |
| Atorvastatin Calcium | 180 | $2,843 |
| Carvedilol | 265 | $2,741 |
| Cyclosporine ModifiedCyclosporine, Modified | 17 | $1,973 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| NovartisEntresto | $20 | $468,995322 claims |
| AstraZenecaFarxiga | $203 | $256,104224 claims |
| Boehringer IngelheimJardiance | $249 | $191,868156 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Oregonon file to place this against a meaningful peer group, so we don't.
Other advanced heart failure and transplant cardiology in Portland
- Joshua RemickPortland$143K
- Christopher ChienPortland$57K
- Jenna KayPortland$37K
- Vidang NguyenPortland$27K
- Conrad MaconPortland$13K
- Johannes SteinerPortland$9K
- Luke MashaPortland$3K
- Nalini ColacoPortland$2K
- Deborah MeyersPortland$2K
- Divya SomanPortland$946
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.